Molecular Profiling In Endocrine Neoplasms
What is this
This trend involves comprehensive molecular profiling of endocrine neoplasms, aiming to differentiate benign from malignant tumors through advanced biomarker analysis. The core idea is to leverage genetic and molecular data to improve diagnosis and tailor treatments in endocrine cancers.
Why it matters
The incidence of endocrine neoplasms is rapidly growing, which creates an urgent need for better diagnostic and therapeutic solutions. With increasing government support and ongoing clinical studies, this emerging field is positioned to significantly impact personalized medicine.
Investment angle
Investors might consider backing biotech companies and startups that focus on precision diagnostics and targeted treatments in oncology. Additionally, investing in specialized biotech ETFs that include firms with molecular diagnostic capabilities could offer diversified exposure to this trend.
A promising but high-risk early-stage biotech opportunity; invest cautiously. Investability: 5/10
History
| date | signals | new | substance |
|---|---|---|---|
| 2026-04-24 | 3 | 100% | |
| 2026-05-02 | 3 | +0 | 100% |
| 2026-05-11 | 3 | +0 | 100% |
| 2026-05-21 | 4 | +1 | 100% |
| 2026-05-30 | 5 | +1 | 100% |
| 2026-06-07 | 5 | +0 | 100% |
| 2026-06-15 | 10 | +5 | 100% |
| 2026-06-24 | 13 | +3 | 100% |
| 2026-07-02 | 13 | +0 | 100% |
| 2026-07-10 | 17 | +4 | 100% |
| 2026-07-19 | 19 | +2 | 100% |
| 2026-07-27 | 22 | +3 | 100% |
| 2026-08-05 | 29 | +7 | 100% |
| 2026-08-13 | 30 | +1 | 100% |
Evidence
- 2026-08-06ClinicalTrials.gov[PHASE2] SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma · detail
- 2026-08-01OpenAlexFolge 1.2: Von Flohsamen, Heilerde und weiteren fruchtbaren Therapiekonzepten bei gastrointestinalen Nebenwirkungen von Tumortherapien · detail
- 2026-07-31ClinicalTrials.gov[PHASE3] A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer · detail
- 2026-07-30PubMedEfficacy of first-line treatment in driver gene-negative non-small cell lung cancer with liver metastases: a Bayesian network meta-analysis. · detail
- 2026-07-29ClinicalTrials.gov[PHASE1] Tumor-Specific T-Cells (cCTL:GL01) for Advanced Gastrointestinal Cancer · detail
- 2026-07-28OpenAlexFrom local control to immune synergy: the evolving role of stereotactic body radiotherapy in the immunotherapy era of hepatocellular carcinoma · detail
- 2026-07-28ClinicalTrials.gov[PHASE2] Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma · detail
- 2026-07-28ClinicalTrials.gov[PHASE2] Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study · detail
- 2026-07-24ClinicalTrials.gov[PHASE2] Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors · detail
- 2026-07-24ClinicalTrials.gov[PHASE2] Dendritic Cell Vaccination to Prevent Hepatocellular Carcinoma Recurrence After Liver Resection - Phase II Clinical Trial · detail
- 2026-07-20ClinicalTrials.gov[PHASE1] A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma · detail
- 2026-07-15ClinicalTrials.gov[PHASE2] Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer · detail
- 2026-07-13CrossrefEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma · detail
- 2026-07-10ClinicalTrials.gov[PHASE3] Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) · detail
- 2026-07-09ClinicalTrials.gov[PHASE3] A Phase III Trial of Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma · detail
- 2026-07-07PubMedDrug-eluting bead TACE improves the efficacy of HAIC combined with molecular-targeted therapy and anti-PD-1 immunotherapy in large hepatocellular carcinoma with inferior vena cava and/or right atrium tumor thrombus: a multicenter retrospective cohort study. · detail
- 2026-07-07ClinicalTrials.gov[PHASE2] Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II · detail
- 2026-06-24PubMedEfficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial. · detail
- 2026-06-22ClinicalTrials.gov[PHASE2] A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement · detail
- 2026-06-17ClinicalTrials.gov[PHASE2] Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC. · detail